Calm investment

Venture investors expect a $14 million series B1 round for respiratory play Pulmatrix Inc. will get its lead candidate to Phase IIa data in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

All of Pulmatrix's existing VCs participated, including Polaris Venture Partners; 5AM Ventures; Arch Venture Partners; and Novartis Venture Fund...